Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115836 | 1.00 | PIN1 (0.47) | PIN1ALDH1A1TRPM8MEN1KMT2A | |
| SCHEMBL17240945 | 0.94 | PIN1 (0.43) | PIN1ALDH1A1TRPM8MEN1KMT2A | |
| SCHEMBL2115838 | 0.92 | MEN1 (0.53) | PIN1ALDH1A1TRPM8MEN1KMT2A | |
| SCHEMBL2115965 | 0.89 | PIN1 (0.45) | PIN1ALDH1A1TRPM8KDM4ECYP1A2 | |
| SCHEMBL2115969 | 0.89 | PIN1 (0.45) | PIN1ALDH1A1TRPM8KDM4ECYP1A2 | |
| SCHEMBL17240946 | 0.85 | MEN1 (0.47) | PIN1ALDH1A1TRPM8MEN1KMT2A | |
| SCHEMBL28619903 | 0.84 | ALDH1A1 (0.46) | PIN1ALDH1A1TRPM8MEN1KMT2A | |
| SCHEMBL2115563 | 0.81 | ALDH1A1 (0.50) | PIN1ALDH1A1TRPM8MEN1KMT2A | |
| SCHEMBL2115566 | 0.81 | ALDH1A1 (0.50) | PIN1ALDH1A1TRPM8MEN1KMT2A | |
| SCHEMBL2115968 | 0.81 | PIN1 (0.45) | PIN1ALDH1A1TRPM8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2015138917-A1 | DIMETHYL FUMARATE AND VACCINATION REGIMENS | BIOGEN MA INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015128492-A1 | MONOMETHYL- AND DIMETHYLFUMARATE FOR NK CELL ACTIVATION | MAGHAZACHI AZZAM A (NO) | 2015-09-03 | — | — | WO | disclosed |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN MA INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2014190056-A2 | PRODRUGS AND DRUGS | BIOGEN IDEC MA INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN MA INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN IDEC MA INC. | 2013-08-22 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885ALDH1A1 3424/4885TRPM8 254/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885ALDH1A1 3424/4885TRPM8 254/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | PIN1 405/4885ALDH1A1 1970/4885TRPM8 1644/4885 |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FH, SLC6A6, SLC6A13 | PIN1 962/4885ALDH1A1 3705/4885TRPM8 53/4885 |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | FH, FAH, MGMT | PIN1 1693/4885ALDH1A1 2678/4885TRPM8 815/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885ALDH1A1 3424/4885TRPM8 254/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885ALDH1A1 3424/4885TRPM8 254/4885 |
| US-20140057918-A1 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof | FH, FAH, DHFR | PIN1 806/4885ALDH1A1 1063/4885TRPM8 3946/4885 |
| US-20210228701-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | PIN1 2070/4885ALDH1A1 3688/4885TRPM8 2004/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | PIN1 1935/4885ALDH1A1 3424/4885TRPM8 254/4885 |
| US-20130216615-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | PIN1 1693/4885ALDH1A1 2678/4885TRPM8 815/4885 |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | PIN1 2070/4885ALDH1A1 3688/4885TRPM8 2004/4885 |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | PIN1 1693/4885ALDH1A1 2678/4885TRPM8 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.